Signup/Login
If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Signup/Login
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
Monitor
IPO today
Upcoming IPO
FGI Industries (FGI)
Verdant Earth Technologies (VDNT)
Modular Medical (MODD)
Jupiter Neurosciences, Inc. (JUNS)
Sunfire Acquisition (SUNFU)
Rhodium Enterprises, Inc. (RHDM)
Four Springs Capital Trust (FSPR)
Samsara Vision (SMSA)
Priced IPO
Yoshitsu Co., Ltd. (TKLF)
Tpg Inc. (TPG)
Hillstream BioPharma (HILS)
Hour Loop (HOUR)
Vigil Neuroscience, Inc. (VIGL)
Amylyx Pharmaceuticals, Inc. (AMLX)
Cincor Pharma, Inc. (CINC)
Apptech (APCX)
NexGel, Inc. (NXGL)
Immix Biopharma (IMMX)
Bionomics Limited (BNOX)
Genenta Science (GNTA)
Samsara Inc. (IOT)
Sidus Space (SIDU)
Fresh Vine Wine, Inc. (VINE)
Nu Holdings Ltd. (NU)
Hashicorp, Inc. (HCP)
NeuroSense Therapeutics Ltd. (NRSN)
Cingulate, Inc. (CING)
Chicago Atlantic Real Estate Finance, Inc. (REFT)
More companies

Incannex Healthcare (IXHL)

Sector - Healthcare

IPO Profile

About company

Since 2019, they have been conducting research and development for synthetic cannabidiol pharmaceutical products and psychedelic medicine therapies for treatment of a range of indications. Their mission is to create first-in-class pharmaceutical drugs and therapies for patients that they believe have unmet medical needs. They aim to be recognized as a leading specialty drug development company at the forefront of innovation, committed to restoring health and transforming the lives of patients through the development of novel pharmaceutical products and treatments. They are developing targeted and scientifically validated fixed-dose combinations of synthetic cannabidiol and psychedelic agents, applying proprietary insights in an effort to create long term value for their patients and shareholders. They focus on clinical indications that they believe represent unmet or inadequately addressed medical needs and also represent compelling commercial opportunities. In particular, they are developing three unique pharmaceutical compositions to target five indications: obstructive sleep apnea (“OSA”), traumatic brain injury (“TBI”)/concussion, rheumatoid arthritis, inflammatory bowel disease and inflammatory lung conditions (“ARDS”, “COPD”, Asthma, Bronchitis). They are also developing a treatment for generalized anxiety disorder (“GAD”) utilizing psilocybin combined with innovative psychotherapy methods.
Industry
Pharmaceutical Preparations
CEO CFO
-
Employees Founded
4 2001

Contacts

Address: Suite 15, Level 12, 401 Docklands Drive Docklands 3008, Victoria Australia

Telephone: + 61 409 840 786

Web page: http://www.incannex.com.au

IPO information

Expected Date 11/29/2021
Status  ! Week of
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
-
Share prices ($)

Shares & Volumes

Shares Initial (MM) 2.5
Shares Revised (MM) -
Expected offer amount (MM) $27
Realized offer amount(MM) -

Financial Data (last reporting year)

Market Cap (MM) -
Revenues (MM) $0.96
Net Income (Loss) (MM) $-3.77

Voting

What do you think will happen with the IXHL share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
The lead left underwriter: Roth Capital

IPOs led by the firm .Pro
Profitability of conducted IPOs  ?  .Pro
1st day change  ?  .Pro
Change for the first 3 months  ?  .Pro
Underwriters
Roth Capital
CO-Managers

Sector: Healthcare

Tweets about $IXHL

Tweets volume:

RT volume:

Timeframe:

Google Trends Stats